Results 351 to 360 of about 1,075,882 (382)
Some of the next articles are maybe not open access.

Carrier solutions for intraperitoneal chemotherapy

Surgical Oncology Clinics of North America, 2003
Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration and nonuniform intraperitoneal distribution by the drug-containing solution. A better understanding of the pharmacodynamics of carrier solutions for intraperitoneal chemotherapy may impact on both these problems.
Faheez, Mohamed, Paul H, Sugarbaker
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on

Cancer, 2019
Patients with advanced epithelial ovarian cancer have a high incidence of peritoneal disease recurrence despite maximal efforts to surgically remove all visible tumor plus intravenous chemotherapy.
S. Koole, W. V. van Driel, G. Sonke
semanticscholar   +1 more source

Neutropenia following Perioperative Intraperitoneal Chemotherapy

Tumori Journal, 1999
Introduction The purpose of this retrospective report was to evaluate clinical features associated with profound neutropenia in patients with peritoneal carcinomatosis who were treated with heated intraoperative intraperitoneal chemotherapy (HIIC) followed by early postoperative intraperitoneal chemotherapy (EPIC).
K J, Schnake, P H, Sugarbaker, D, Yoo
openaire   +2 more sources

Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival

Journal of Surgical Oncology, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective in select patients with peritoneal carcinomatosis (PC). Signet ring cell (SRC) pathology is associated with poor prognosis.
D. Solomon   +8 more
semanticscholar   +1 more source

[Hyperthermic intraperitoneal chemotherapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion.
H, Leebmann, P, Piso
openaire   +1 more source

Intraperitoneal Chemotherapy

Nihon rinsho. Japanese journal of clinical medicine, 2013
Ying Xiao   +56 more
openaire   +3 more sources

[Intraperitoneal chemotherapy].

Gan to kagaku ryoho. Cancer & chemotherapy, 1989
A fact that the Second International Conference of Intracavitary Chemotherapy was held at Sandiego in 1988 clearly suggests that the intraperitoneal chemotherapy attracts again the attention as a new administration route aimed at complete cure and useful modality against refractory intraabdominal cancer.
openaire   +1 more source

Intraperitoneal Chemotherapy

Annals of Internal Medicine, 1984
R F, Ozols, C E, Myers, R C, Young
openaire   +2 more sources

Intraperitoneal chemotherapy

Gynecologic Oncology, 1985
P. Braly, J. Doroshow, P. DiSaia
openaire   +1 more source

Home - About - Disclaimer - Privacy